Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05553145 · ClinicalTrials.gov registry record

The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care

A clinical trial, sponsored by The Cleveland Clinic.

Completed
Registry status
200
Enrollment target

NCT05553145 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05553145 has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
200 participants
Enrollment target

Study Summary

The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.

Interventions

  • DIAGNOSTIC_TEST Autoimmune Antibody Assays

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2022-09-01
Est. Completion 2024-08-29

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT05553145

The ClinicalTrials.gov registry entry for NCT05553145 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Autoimmune Antibody Assays is the first listed.

NCT05553145 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05553145 about?

NCT05553145 is a clinical study titled "The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care". The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.

What is the current status of trial NCT05553145?

This trial is currently completed. The enrollment target is 200 participants. The study started on 2022-09-01. Estimated completion is 2024-08-29.

What interventions are being tested in trial NCT05553145?

The interventions under investigation include: Autoimmune Antibody Assays (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05553145?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.